The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy
Abstract
Purpose: Studies in cancer patients with venous thromboembolism suggested that low molecular weight heparin may prolong survival. In a double-blind study, we evaluated the effect of low molecular weight heparin on survival in patients with advanced malignancy without venous thromboembolism. Methods: Patients with metastasized or locally advanced solid tumors were randomly assigned to receive a 6-week course of subcutaneous nadroparin or placebo. The primary efficacy analysis was based on time from random assignment to death. The primary safety outcome was major bleeding. Results: In total, 148 patients were allocated to nadroparin and 154 patients were allocated to placebo. Mean follow-up was 1 year. In the intention-to-treat analysis the overall hazard ratio of mortality was 0.75 (95% CI, 0.59 to 0.96) with a median survival of 8.0 months in the nadroparin recipients versus 6.6 months in the placebo group. After adjustment for potential confounders, the treatment effect remained statistically significant. Major bleeding occurred in five (3%) of nadroparin-treated patients and in one (1%) of the placebo recipients (P = .12). In the a priori specified subgroup of patients with a life expectancy of 6 months or more at enrollment, the hazard ratio was 0.64 (95% CI, 0.45 to 0.90) with a median survival of 15.4 and 9.4 months, respectively. For patients with a shorter life expectancy, the hazard ratio was 0.88 (95% CI, 0.62 to 1.25). Conclusion: A brief course of subcutaneous low molecular weight heparin favorably influences the survival in patients with advanced malignancy and deserves additional clinical evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Weitz, J. I. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371007 · Cited by 1,533
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa035451 · Cited by 887
Prandoni, P., Carta, M., Cogo, A., Ruol, A., Vigo, M., Casara, D., Lensing, A. W. A., Büller, H. R., & ten Cate, J. W. (1992) · The Lancet · doi:10.1016/0140-6736(92)91054-c · Cited by 583
Self-citationTissue Factor, Thrombin, and Cancer
Rickles, F. R., Patierno, S., & Fernandez, P. M. (2003) · Chest · doi:10.1378/chest.124.3_suppl.58s · Cited by 378
Zacharski, L. R., Henderson, W. G., Rickles, F. R., Forman, W. B., Cornell, C. J., Forcier, A. J., Edwards, R. L., Headley, E., Kim, S.-H., O'Donnell, J. F., et al. (1984) · Cancer · doi:10.1002/1097-0142(19840515)53:10<2046::aid-cncr2820531007>3.0.co;2-f · Cited by 343
The Complex Effects of Heparins on Cancer Progression and Metastasis in Experimental Studies
Smorenburg, S. M., & Van Noorden, C. J. F. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01481-9 · Cited by 294
Self-citationSubcutaneous heparin treatment increases survival in small cell lung cancer
Lebeau, B., Chastang, C., Brechot, J.-M., Capron, F., Dautzenberg, B., Delaisements, C., Mornet, M., Brun, J., Hurdebourcq, J.-P., & Lemarie, E. (1994) · Cancer · doi:10.1002/1097-0142(19940701)74:1<38::aid-cncr2820740108>3.0.co;2-e · Cited by 277
Do Heparins Do More than Just Treat Thrombosis? The Influence of Heparins on Cancer Spread
Hettiarachchi, R., Smorenburg, S., Ginsberg, J., Levine, M., Prins, M., & Büller, H. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615937 · Cited by 206
Self-citationChahinian, A. P., Propert, K. J., Ware, J. H., Zimmer, B., Perry, M. C., Hirsh, V, Skarin, A., Kopel, S., Holland, J. F., & Comis, R. L. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.993 · Cited by 193
The Effects of Unfractionated Heparin on Survival in Patients with Malignancy – A Systematic Review
Smorenburg, S. M., Hettiarachchi, R., Vink, R., & Büller, H. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614885 · Cited by 89
Self-citationFrom Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer
Levine, M. N., Lee, A. Y., & Kakkar, A. K. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00275.x · Cited by 81
Lebeau, B., Chastang, C., Muir, J., Vincent, J., Massin, F., Fabre, C., & Petites Cellules Group (1993) · Cancer · doi:10.1002/1097-0142(19930301)71:5<1741::aid-cncr2820710507>3.0.co;2-q · Cited by 49
Cited by
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Prevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Lyman, G. H., Khorana, A. A., Falanga, A., Clarke-Pearson, D., Flowers, C., Jahanzeb, M., Kakkar, A., Kuderer, N. M., Levine, M. N., Liebman, H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1283 · Cited by 952
Lyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003442 · Cited by 893
Italiano, J. E., Richardson, J. L., Patel-Hett, S., Battinelli, E., Zaslavsky, A., Short, S., Ryeom, S., Folkman, J., & Klement, G. L. (2008) · Blood · doi:10.1182/blood-2007-09-113837 · Cited by 859
Metadata
- Authors
- Klerk, C. P. W., Smorenburg, S. M., Otten, H.-M., Lensing, A. W. A., Prins, M. H., Piovella, F., Prandoni, P., Bos, M. M. E. M., Richel, D. J., van Tienhoven, G., & Büller, H. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-04-01
- Volume
- 23
- Issue
- 10
- Pages
- 2130-2135
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2160638301
- Cited by
- 596
- References
- 18
- FWCI
- 41.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.